Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.10T
Market cap1.10T
Price-Earnings ratio
39.58
Price-Earnings ratio39.58
Dividend yield
0.57%
Dividend yield0.57%
Average volume
2.27M
Average volume2.27M
High today
$1,180.47
High today$1,180.47
Low today
$1,139.33
Low today$1,139.33
Open price
$1,145.85
Open price$1,145.85
Volume
1.05M
Volume1.05M
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$712.05
52 Week low$712.05

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,168.23, giving the company a market capitalization of 1.1T. It carries a P/E multiple of 39.58 and pays a dividend yield of 0.57%.

On 2026-09-22, Eli Lilly(LLY) stock traded between a low of $1,139.33 and a high of $1,180.47. Shares are currently priced at $1,168.23, which is +2.5% above the low and -1.0% below the high.

The Eli Lilly(LLY)'s current trading volume is 1.05M, compared to an average daily volume of 2.27M.

During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.

LLY News

Quartz 3h
Eli Lilly CEO Dave Ricks: 70% of new Medicare GLP-1 patients on Lilly drugs - qz.com

...

Eli Lilly CEO Dave Ricks: 70% of new Medicare GLP-1 patients on Lilly drugs - qz.com
Benzinga 5h
Eli Lilly CEO Says Foundayo Wins One-Third of New Oral GLP-1 Patients as Company Captures 70% of New Seniors: 'Growing Week on Week'

Eli Lilly and Co.‘s (NYSE:LLY) CEO Dave Ricks announced a significant increase in the use of GLP-1 treatments among seniors, following Medicare’s July decision...

Eli Lilly CEO Says Foundayo Wins One-Third of New Oral GLP-1 Patients as Company Captures 70% of New Seniors: 'Growing Week on Week'
Investor's Business Daily 5h
Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.

Technology Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall. Licensing Viking Therapeutics and Roche both reported positive trial data...

Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

24/7 Wall St. 5h
Eli Lilly's Tough Month: One of The Biggest Global Banks Says 37% Gains Begin Soon

Investing Eli Lilly’s Tough Month: One of The Biggest Global Banks Says 37% Gains Begin Soon Eli Lilly just posted a quarter that crushed estimates on every maj...

Eli Lilly's Tough Month: One of The Biggest Global Banks Says 37% Gains Begin Soon
TipRanks 10h
Analyst Boosts Long-Term Growth Forecasts and Reiterates Buy on Eli Lilly Amid Pipeline and Label Momentum

TD Cowen analyst Steve Scala maintained a Buy rating on Eli Lilly & Co today and set a price target of $1,250.00. Steve Scala has given his Buy rating due to a...

Seeking Alpha 22h
Eli Lilly CEO Ricks sees more Foundayo growth with foreign markets

Eli Lilly (NVO) CEO David Ricks said he is optimistic that the drugmaker's oral weight loss pill Foundayo (orforglipron) will continue to increase its market sh...

Eli Lilly CEO Ricks sees more Foundayo growth with foreign markets
Nasdaq 22h
Eli Lilly Stock Is On Track to Do Something It Hasn't Done Since 2016

Key Points Eli Lilly's stock is having an off year by its standards. The last time it didn't generate at least a double-digit return for its shareholders was...

Eli Lilly Stock Is On Track to Do Something It Hasn't Done Since 2016
TipRanks 23h
Eli Lilly Stock Rises After Company Provides Update on Obesity Pill Sales

Eli Lilly’s (LLY) stock is up about 2% on the afternoon of Sept. 21 after the company provided an update on sales of its weight-loss pill called “Foundayo.” In...

Simply Wall St 23h
What Lilly Stock's Breast Cancer Drug Approval Means For Shareholders

Eli Lilly received full U.S. FDA approval for Inluriyo, an oral estrogen receptor antagonist, in combination with Verzenio for adults with ER+, HER2–, ESR1-muta...

What Lilly Stock's Breast Cancer Drug Approval Means For Shareholders
TipRanks 24h
Eli Lilly’s LY3971297 Trial Completion Signals Next Steps in Cardio-Metabolic Pipeline

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The study A Single-ascending and Multiple-ascending Dose Study of LY3971297 te...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.